Your Health, We Care
The efficacy of Ivosidenib in the treatment of AML has been further validated. Companies such as R&D manufacturer Agios continue to promote the clinical development and commercialization of Ivosidenib to meet the treatment needs of more patients.
As a monotherapy for locally advanced or metastatic cholangiocarcinoma patients with IDH1 R132 mutations, Ivosidenib has also achieved positive results.
Is the Lao Lucius version of Ivosidenib available on the market?Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor, has shown clinical benefits in patients with acute myelo···【more】
Article source：Lucius LaosRelease date：2024-11-28Recommended：101
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
